FluoRib: impact of chemotherapy on cancer cells' behavior


Chemotherapy is widely used to treat cancer. Some chemical agent is the active principal of the drug. The most used chemical is known as 5-Fluorouracil (5-FU).

This project investigates the impact of the 5-FU on the behavior of cancer cells. It tries to determine whether it influences the way these cells build their proteins.

Scientific abstract:

The chemotherapeutic agent 5-Fluorouracil (5-FU) is the first line treatment for colorectal cancer (CRC) patients. Despite novel targeted therapies used in combination with 5-FU based on chemotherapies, resistance to these treatments and metastasis formation remain major challenges to overcome. Resistance and tumor dissemination are achieved by multi-step reprogramming of gene expression and require a tremendous cellular adaptability, a process known as plasticity. Translation is one of the last levels of gene expression regulation and ribosome is the major effector of translation. Therefore, resistance to 5-FU might be explained by the impact of 5-FU on ribosome and consequently on translation. Using CRC cell lines, Partner 1, Partner 2 and Partner 3 already showed that 5-FU (i) creates F-ribosomes (ribosomes having incorporated 5-FU), (ii) induces a global translational reprogramming, (iii) pushes cancer cells towards pluripotency-like phenotype. The objective of FluoRib is to demonstrate that the translational reprogramming induced by 5-FU incorporation in rRNA does explain 5-FU driven plasticity.


INCA (French National Institute for Cancer Research) INCA (National Institute for Cancer Research

Eric Rivals
CNRS Research Director in Computer Science and Bioinformatics

My research interests include string algorithms, bioinformatics, genomics.


Welcome Benoît